Literature DB >> 2433353

Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter.

L Karawajew, B Micheel, O Behrsing, M Gaestel.   

Abstract

Hybrid hybridomas (tetradomas) producing bispecific monoclonal antibodies reacting with both horseradish peroxidase (HRP) and human alpha-fetoprotein (AFP) were obtained by fusing two hybridoma lines and selecting the fused cells by a fluorescence activated cell sorter (FACS III). The hybridoma cells were labelled before fusion with fluorescein isothiocyanate (FITC) and tetramethyl rhodamine isothiocyanate (TRITC) respectively and heterofluorescent cells were sorted out after fusion. Several clones were found to produce bispecific antibodies, and one clone, designated T1, was subjected to growth in ascitic fluid in mice in order to obtain large quantities of hybrid antibodies. Bispecific antibodies could be separated from the monospecific antibody populations by one-step hydroxylapatite chromatography. SDS-polyacrylamide gel electrophoresis demonstrated that the hybrid antibody molecules contained the heavy chains of both anti-HRP and anti-AFP origin. The bispecific antibodies were used to build up a sensitive two-site binding enzyme immunoassay.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433353     DOI: 10.1016/0022-1759(87)90323-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

Review 1.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.

Authors:  L K Gilliland; M R Clark; H Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

Review 3.  Bispecific antibodies: design, therapy, perspectives.

Authors:  Sergey E Sedykh; Victor V Prinz; Valentina N Buneva; Georgy A Nevinsky
Journal:  Drug Des Devel Ther       Date:  2018-01-22       Impact factor: 4.162

4.  A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.

Authors:  M V Pimm; R A Robins; M J Embleton; E Jacobs; A J Markham; A Charleston; R W Baldwin
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

5.  Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody.

Authors:  K Okamoto; K Harada; S Ikeyama; S Iwasa
Journal:  Jpn J Cancer Res       Date:  1992-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.